Biologics for chronic rhinosinusitis with nasal polyps: a real-world prospective cohort study.

M Blauwblomme; A-S Viskens; E Bonne; E Borgers; C Cox; G De Vos; L Derycke; A-S Eeckels; S Halewyck; V Hox; P Janssen; P Janssen; W Lemmens; F Rogister; K Speleman; M Syssauw; O Vanderveken; E Vandewalle; S Vanhee; B Verhaeghe; A V Vroegop; T Van Zele; P Gevaert; P W Hellings

doi:10.4193/rhin26.004

Key Points

The study aims to assess the real-world efficacy of biologics in treating chronic rhinosinusitis with nasal polyps (CRSwNP).
Conducted a real-world prospective cohort analysis
Included patients with severe chronic rhinosinusitis with nasal polyps
Evaluated the clinical benefits of three registered biologics
Significant clinical benefit observed with all three biologics
Larger improvements noted in patients treated with dupilumab

Implication

Real-world cohort study shows that biologics improve clinical outcomes in chronic rhinosinusitis with nasal polyps, suggesting their effectiveness.

Abstract

In this real-world cohort, the three registered biologics provided significant clinical benefit in severe CRSwNP, with numerically larger improvements observed in patients treated with dupilumab.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Blauwblomme et al. (2026) studied this question.

synapsesocial.com/papers/69e31f9e40886becb653eddc https://doi.org/10.4193/rhin26.004

View at Publisher

Ask AI

Bookmark

Share

Biologics for chronic rhinosinusitis with nasal polyps: a real-world prospective cohort study.

Key Points

Implication

Abstract

Discussion

Cite This Study

Biologics for chronic rhinosinusitis with nasal polyps: a real-world prospective cohort study.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers